Crohn’s Disease May Lessen Soliris’ Effectiveness in aHUS Patients

Crohn’s Disease May Lessen Soliris’ Effectiveness in aHUS Patients

304665

Crohn’s Disease May Lessen Soliris’ Effectiveness in aHUS Patients

Relapses of Crohn’s disease, an inflammatory bowel condition, lessened the efficacy of Soliris (eculizumab) in an adolescent girl with atypical hemolytic uremic syndrome (aHUS), a case study reported. “Increased doses of [Soliris] may be necessary to maintain therapeutic blood levels of [Soliris] and full complement blockade, especially if the intestinal disease is not under control,” the researchers noted. The study, “Atypical HUS and Crohn’s disease—interference of intestinal disease activity with complement-blocking treatment,” was published in…

You must be logged in to read/download the full post.